Serous Endometrial Intraepithelial Carcinoma: Case Report and Literature Review

Mayuko Kawata\textsuperscript{a, b}, Ai Miyoshi\textsuperscript{a}, Eri Fujikawa\textsuperscript{a}, Serika Kanao\textsuperscript{a}, Masumi Takeda\textsuperscript{a}, Mayuko Mimura\textsuperscript{a}, Masaaki Nagamatsu\textsuperscript{a}, Takeshi Yokoia

Abstract

Serous endometrial intraepithelial carcinoma (SEIC) is a rare but highly aggressive form of uterine endometrial cancer. We present a case of a premenopausal 42-year-old patient who presented with copious vaginal bleeding without a specific medical history. A total abdominal hysterectomy was performed. Pathologic results showed SEIC. We report this case and include a brief literature review.

Keywords: Serous endometrial intraepithelial carcinoma; Endometrial carcinoma; Immunohistochemistry

Introduction

Today in Japan, endometrial carcinoma (EC) is the most common malignancy of the female genitals. The majority of EC are type 1 estrogen-related tumors of early-stage and low-grade, with a 5-year survival rate of greater than 85\% [1].

The second type of EC is the non-estrogen-related type 2 tumors, the most common of which is the serous endometrial adenocarcinoma (SEC). Type 2 EC makes up the preponderance of all EC mortality. Tumor recurrence and death have occurred even when the SEC was thought confined to the endometrium [2, 3].

The serous endometrial intraepithelial carcinoma (SEIC) is limited to the uterine epithelium, but has been shown to be the precursor of invasive SEC. SEIC can be a difficult histopathological diagnosis without ancillary immunohistochemistry [4]. This diagnostic ambiguity is critical because molecular studies have shown that SEIC is commonly the source of extra-uterine metastasis, making it a uniquely aggressive disease [5, 6].

We experienced an unusual case of a premenopausal woman diagnosed with SEIC. We report on this rare case, and provide a brief review of the SEIC literature.

Case Report

A 42-year-old premenopausal woman (gravida 3) presented to our hospital with copious atypical genital bleeding. She had no previous history of such bleeding or related symptoms. During internal examination, roughly 300 mL of blood with clots was observed in the vagina. Transvaginal ultrasound found no abnormalities in the uterus, endometrium thickness or ovaries. Magnetic resonance imaging (MRI) detected hematometra and an endometrial polyp 13 mm in diameter.

For hemostasis, a total abdominal hysterectomy was performed. The gross appearance of the resected uterus was normal for a 43-year-old female. There was a small round elevated lesion (polyp) arising from the posterior wall of the uterus. The cross-section of the polyp featured a spongiform structure (Fig. 1).

Histologically, cystoid growths spanned the polyp, forming confluent glands measuring 3 - 4 mm in diameter. The tumor cells formed multiple layers and had large nuclei with irregular eosinophilic nucleoli, with a hobnail appearance (Fig. 2). Immunohistochemistry showed that the tumor cells were p53 positive (Fig. 3), estrogen receptor (ER) negative (Fig. 4), and CK18 (Fig. 4).

Figure 1. Histological findings of polyp from the posterior uterine wall endometrium. A cystoid tumor spanned the uterine lesion by forming confluent glands (H&E stain; original magnification × 40).
and progesterone receptor (PgR) negative (Fig. 5). After surgery, computerized tomography (CT) found no metastasis. To detect metastatic lesions, we performed a bilateral salpingo-oophorectomy, partial omentectomy, and pelvic and para aortic lymph node dissections. Histopathological examination found no metastatic lesions in the ovaries, lymph nodes or omentum. The final diagnosis was of an SEIC.

Six cycles of adjuvant chemotherapy with paclitaxel, doxorubicin and carboplatin, given at 3 week intervals, were postoperatively conducted. At 9 months postoperation, there was no sign of recurrence.

Discussion

Historically, SEIC has been discussed either as an “immediate precursor” or an “early form” of SEC, i.e., the latter infers in situ serous adenocarcinoma, also sometimes called “minimal uterine serous cancer” (MUSC). Regardless of terminology, SEIC is clearly the major SEC precursor, as 100% of SEC that had associated concurrent SEIC had concordant genetic markers (mutations) in both components [7].

SEIC and SEC occur mostly at postmenopausal age, which is one of the characteristics that makes our premenopausal case so remarkably rare. Even when you know to look for it, SEIC is difficult to detect because the lesion is usually focal and small. Occasionally it forms a distinctive polyp. SEIC lesions have atypical endometrial glands with pseudostratification of the lining cells, which are relatively large, with markedly atypical “hobnail” nuclei due to prominent nucleoli.

During progression, SEIC evolves into SEC through multiple molecular pathways [8]. TP53 gene mutations (which appear to be important in the conversion of atrophic endometrium into SEIC) and p53 protein overexpression (p53 signatures) are frequently the earliest hallmarks of SEIC. Immunohistochemical stains for p53 (positive), ER (negative), PgR
There was no funding source for this research.

References


Acknowledgments

The authors thank Dr. GS Buzard for his editing of the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest regarding this paper.

Financial Support

There was no funding source for this research.